This segment focuses on the research and development of cancer metabolism-based therapies (CMBTs) designed to target the unique metabolic vulnerabilities of cancer cells. The lead candidate, SM-88, is undergoing Phase II/III clinical trials across a spectrum of cancer types, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. Research activities involve in-depth analysis of cancer cell gene expression, epigenetic modifications, and metabolic changes following SM-88 treatment, conducted in collaboration with institutions like Mayo Clinic and NYU School of Medicine. The goal is to develop broadly effective cancer treatments with improved patient outcomes and reduced toxicity compared to traditional chemotherapy. Future opportunities include expanding the application of CMBTs to additional cancer types and exploring combination therapies.

This segment is dedicated to the preclinical development of TYME-19, an orally administered synthetic bile acid analog, for the treatment of COVID-19 and its variants. Research efforts are focused on understanding the mechanism of action of TYME-19 and its potential to inhibit viral replication and reduce inflammation associated with COVID-19 infection. The therapeutic area addresses the urgent need for effective and accessible treatments for COVID-19, particularly in light of emerging variants. Future opportunities include advancing TYME-19 into clinical trials and exploring its potential as a prophylactic agent. Regulatory and clinical aspects will be critical in determining the path forward for this therapeutic candidate.

This segment is focused on the preclinical development of TYME-18, a CMBT compound designed for the treatment of inoperable tumors. Research activities involve investigating the compound's efficacy and safety in preclinical models, with the goal of identifying optimal dosing regimens and potential biomarkers for patient selection. The therapeutic area addresses the unmet need for effective treatments for tumors that cannot be surgically removed. Future opportunities include advancing TYME-18 into clinical trials and exploring its potential in combination with other therapies. Regulatory and clinical aspects will be critical in determining the path forward for this therapeutic candidate.